Anika Therapeutics | ANIK - Selling And Administration Expenses


Anika Therapeutics reported $10.01M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
Agenus USD 6.21M 4.34M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.47M 208K Jun/2026
Integra LifeSciences USD 166.22M 12.01M Jun/2026
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.63B 307M Jun/2026
Smith & Nephew USD 1.45B 29M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Veracyte USD 55.71M 4.87M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026
Zimmer Biomet Holdings USD 911.6M 61.7M Jun/2026